QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Talimogene Laherparepvec, Oncolytic HSV-1 and Product Pharmacovigilance

Test your understanding of the concepts covered by Talimogene Laherparepvec: Oncolytic HSV-1, Melanoma and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which clinical feature should prompt evaluation beyond an assumed expected flu-like reaction?

Brief fatigue after injection Mild transient chills Persistent high fever with hypotension or focal infectious symptoms Short-lived nausea without other findings

Question 2 of 10 A patient develops a cold sore after treatment. Which is the most appropriate initial pharmacovigilance interpretation?

It must be infection with the therapeutic strain It must be reactivation of wild-type HSV-1 The event is compatible with several explanations and requires clinical and, where possible, virological assessment It should be excluded because cold sores are unrelated to HSV biology

Question 3 of 10 Why can swelling or inflammation of an injected lesion be difficult to interpret as treatment failure?

The product has no local biological activity Oncolysis and immune activation can produce inflammatory enlargement that may resemble progression Injected lesions cannot undergo necrosis Inflammation proves that the lesion contains wild-type HSV-1

Question 4 of 10 Which statement best distinguishes viral DNA detection from evidence of transmissible infection?

Any viral DNA signal proves that replication-competent virus was transmitted PCR cannot detect viral material from a lesion Viral DNA may be detected without demonstrating infectious, replication-competent virus Recovery of infectious virus is less informative than an isolated DNA result

Question 5 of 10 Why is lesion accessibility clinically important when selecting patients for talimogene laherparepvec?

Accessible lesions are required for repeated direct delivery of the medicine Accessible lesions are less likely to contain melanoma cells The product is effective only when administered intravenously through a lesion Lesion accessibility eliminates the possibility of systemic immune effects

Question 6 of 10 Which characteristic most directly explains why talimogene laherparepvec requires pharmacovigilance controls beyond those used for an ordinary injectable protein?

It is administered only to patients with melanoma It is a replication-competent genetically modified HSV-1 It contains a human cytokine gene It is given by intralesional injection

Question 7 of 10 Which information is most important when assessing possible transmission to a household contact?

Only the patient's tumour stage Whether the contact had direct contact with lesions, dressings or contaminated material Only the patient's fatigue score Whether the patient previously received surgery, regardless of exposure

Question 8 of 10 What is the most relevant pharmacological consequence of deleting ICP47 as described in the article?

Improved antigen presentation and altered viral gene expression Elimination of the need for intralesional administration Direct production of bacterial antibodies Complete prevention of viral shedding

Question 9 of 10 Which factor would be least appropriate to omit when evaluating impaired healing of an injected lesion?

The lesion's size and condition before treatment History of prior surgery or radiation at the site Culture findings and wound-care measures The patient's preferred method of travel to the clinic

Question 10 of 10 Which interpretation of tumour selectivity is most accurate for talimogene laherparepvec?

The virus can replicate only in malignant cells under all circumstances Tumour selectivity reflects a shifted balance favouring tumour replication, while residual biological risk remains The virus is non-replicating after injection into a tumour Normal tissues are protected because HSV-1 cannot infect human cells

Knowledge Assessment: Talimogene Laherparepvec, Oncolytic HSV-1 and Product Pharmacovigilance

Cookie Settings